AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Attention Deficit Hyperactivity Disorder Clinical Trial Pipeline Highlights 2019 - Forecast to 2024 by Clinical Stage, Drug Mechanism Classes, & Companies - ResearchAndMarkets.com

June 13, 2019

DUBLIN--(BUSINESS WIRE)--Jun 13, 2019--

The “Global Attention Deficit Hyperactivity Disorder Clinical Trial Pipeline Highlights - 2019” report has been added to ResearchAndMarkets.com’s offering.

Attention Deficit Hyperactivity Disorder Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Attention Deficit Hyperactivity Disorder market.

It covers emerging therapies for Attention Deficit Hyperactivity Disorder in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Attention Deficit Hyperactivity Disorder pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Attention Deficit Hyperactivity Disorder pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Attention Deficit Hyperactivity Disorder pipeline products by the company.

Short-term Launch Highlights:

Find out which Attention Deficit Hyperactivity Disorder pipeline products will be launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Attention Deficit Hyperactivity Disorder Pipeline by Stages

2. Attention Deficit Hyperactivity Disorder Phase 3 Clinical Trial Insights

3. Attention Deficit Hyperactivity Disorder Phase 2 Clinical Trial Insights

4. Attention Deficit Hyperactivity Disorder Phase 1 Clinical Trial Insights

5. Attention Deficit Hyperactivity Disorder Preclinical Research Insights

6. Attention Deficit Hyperactivity Disorder Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/2ocehs

View source version on businesswire.com:https://www.businesswire.com/news/home/20190613005256/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials,Mental Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 06/13/2019 05:20 AM/DISC: 06/13/2019 05:20 AM

http://www.businesswire.com/news/home/20190613005256/en

All contents © copyright 2019 The Associated Press. All rights reserved.